$0.69
12.25% yesterday
Nasdaq, Nov 15, 09:49 pm CET
ISIN
US23254X2018
Symbol
CYTH
Sector
Industry

Cyclo Therapeutics Inc - Ordinary Shares - Class A Target price 2024 - Analyst rating & recommendation

Cyclo Therapeutics Inc - Ordinary Shares - Class A Classifications & Recommendation:

Buy
33%
Hold
67%

Cyclo Therapeutics Inc - Ordinary Shares - Class A Price Target

Target Price $2.48
Price $0.70
Potential
Number of Estimates 2
2 Analysts have issued a price target Cyclo Therapeutics Inc - Ordinary Shares - Class A 2025 . The average Cyclo Therapeutics Inc - Ordinary Shares - Class A target price is $2.48. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 3 analysts: 1 Analysts recommend Cyclo Therapeutics Inc - Ordinary Shares - Class A to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Cyclo Therapeutics Inc - Ordinary Shares - Class A stock has an average upside potential 2025 of . Most analysts recommend the Cyclo Therapeutics Inc - Ordinary Shares - Class A stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 1.08 0.97
21.74% 10.53%
Net Margin -3,276.58% -2,024.52%
14.12% 38.21%

3 Analysts have issued a sales forecast Cyclo Therapeutics Inc - Ordinary Shares - Class A 2024 . The average Cyclo Therapeutics Inc - Ordinary Shares - Class A sales estimate is

$966k
Unlock
. This is
11.07% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.2m 37.93%
Unlock
, the lowest is
$572k 34.25%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.1m 21.74%
2024
$966k 10.53%
Unlock
2025
$1.2m 24.53%
Unlock
2026
$14.5m 1,107.76%
Unlock
2027
$32.7m 125.31%
Unlock
2028
$91.6m 179.68%
Unlock

2 Cyclo Therapeutics Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2024. The average Cyclo Therapeutics Inc - Ordinary Shares - Class A net profit estimate is

$-19.6m
Unlock
. This is
24.46% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-17.0m 34.46%
Unlock
, the lowest is
$-22.2m 14.46%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-35.4m 32.79%
2024
$-19.6m 44.73%
Unlock
2025
$-19.1m 2.20%
Unlock
2026
$-3.7m 80.45%
Unlock
2027
$10.1m 369.25%
Unlock
2028
$36.8m 265.74%
Unlock

Net Margin

2023 -3,276.58% 14.12%
2024
-2,024.52% 38.21%
Unlock
2025
-1,589.92% 21.47%
Unlock
2026
-25.74% 98.38%
Unlock
2027
30.75% 219.46%
Unlock
2028
40.21% 30.76%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.23 -0.68
32.79% 44.72%
P/E negative
EV/Sales 32.37

2 Analysts have issued a Cyclo Therapeutics Inc - Ordinary Shares - Class A forecast for earnings per share. The average Cyclo Therapeutics Inc - Ordinary Shares - Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.68
Unlock
. This is
24.44% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.59 34.44%
Unlock
, the lowest is
$-0.77 14.44%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.23 32.79%
2024
$-0.68 44.72%
Unlock
2025
$-0.67 1.47%
Unlock
2026
$-0.13 80.60%
Unlock
2027
$0.35 369.23%
Unlock
2028
$1.28 265.71%
Unlock

P/E ratio

Current -0.78 9.86%
2024
-1.03 32.05%
Unlock
2025
-1.05 1.94%
Unlock
2026
-5.38 412.38%
Unlock
2027
2.00 137.17%
Unlock
2028
0.55 72.50%
Unlock

Based on analysts' sales estimates for 2024, the Cyclo Therapeutics Inc - Ordinary Shares - Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

32.37
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
20.70
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 35.95 31.35%
2024
32.37 9.96%
Unlock
2025
25.99 19.70%
Unlock
2026
2.15 91.72%
Unlock
2027
0.96 55.61%
Unlock
2028
0.34 64.24%
Unlock

P/S ratio

Current 22.99 18.60%
2024
20.70 9.97%
Unlock
2025
16.62 19.70%
Unlock
2026
1.38 91.72%
Unlock
2027
0.61 55.62%
Unlock
2028
0.22 64.24%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today